AstraZeneca's Etcamah Fails Pivotal Breast Cancer Study
Product·2 articles across 2 outlets
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
AstraZeneca's Etcamah, a newly approved oral SERD, has failed to improve outcomes in a pivotal breast cancer study. This result could limit the use of the medicine in frontline treatment for breast cancer.
The failure marks the second oral SERD to recently fall short in first-line breast cancer studies, raising concerns about the effectiveness of this class of drugs in treating the disease.
AstraZeneca
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“<figure><div><img”
biopharma dive — AstraZeneca’s newly approved pill fails frontline breast cancer study“A pill from AstraZeneca failed to improve outcomes in closely watched breast cancer study, a result that could limit the use of the medicine.”
stat news — STAT+: Breast cancer pill from AstraZeneca misses mark in pivotal trial